Blueprint Medicines, a company discovering and developing highly selective investigational kinase medicines for patients with genomically defined diseases, has appointed Kathryn (Kate) Haviland as Chief Business Officer, who will be responsible for the firm’s corporate strategy, business development, corporate communications and investor relations functions.
“Haviland’s substantial background in business development, commercial and strategic planning and program management will be indispensable as we continue to explore the depth of our pipeline of highly selective investigational kinase medicines and discover additional applications for our novel target discovery engine,” said Jeff Albers, CEO of Blueprint.
“With two Phase 1 clinical trials underway, FDA authorization to begin a third clinical trial and multiple discovery efforts, Blueprint Medicines is poised to develop meaningful medicines for patients with genomically defined diseases, and I am excited to lend my expertise to further advance these efforts,” stated Haviland.
Haviland joined from Idera Pharmaceuticals, where she served as Vice President, Rare Diseases and Oncology Program Leadership. She oversaw all aspects of the product development strategy for Idera ‘ rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution, and commercial planning. Prior to this, she was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, she previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme.
Meanwhile, Blueprint Medicines promoted Anthony (Andy) Boral to Chief Medical Officer. Boral joined Blueprint in February 2015 as Senior Vice President, Clinical Development, and has been instrumental in building Blueprint Medicines clinical development organization and advancing BLU-554 and BLU-285 into Phase 1 clinical trials. Prior to joining Blueprint, he was Executive Director, Oncology Clinical Research at the Novartis Institutes for BioMedical Research, and also served as Deputy Site Head for Novartis’s Cambridge, Mass location.
Based in Cambridge, Mass, Blueprint is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumours, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development.